Navigation Links
Licorice compound offers new cancer prevention strategy
Date:3/23/2009

A chemical component of licorice may offer a new approach to preventing colorectal cancer without the adverse side effects of other preventive therapies, Vanderbilt University Medical Center researchers report.

In the study published in the Journal of Clinical Investigation, Raymond Harris, M.D., Ming-Zhi Zhang, M.D., and colleagues show that inhibiting the enzyme 11β-hydroxysteroid dehydrogenase type 2 (11βHSD2) either by treatment with a natural compound found in licorice or by silencing the 11βHSD2 gene prevents colorectal cancer progression in mice predisposed to the disease.

Colorectal cancer is the second leading cause of cancer deaths in the United States. While prevention is the best approach for reducing colorectal cancer deaths, few medical strategies exist to prevent the disease.

One promising target for chemoprevention is the enzyme cyclooxygenase 2 (COX-2), which promotes colorectal cancer progression via the action of the enzyme's inflammatory products, the prostaglandins. Inhibiting this enzyme with non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen or with selective COX-2 inhibitors like Vioxx or Celebrex reduces the number and size of colon polyps in mice and in patients with an inherited predisposition to colon cancer. However, both types of drugs cause serious adverse side effects that limit their utility for chemoprevention.

Harris and Zhang nephrologists who are also members of the Vanderbilt-Ingram Cancer Center have been investigating COX-2 regulation in the kidney. They previously found that inhibiting 11βHSD2 in the kidney suppresses COX-2 expression in that organ.

The colon is one of the only other organs (besides the kidney) with high expression of 11βHSD2, suggesting that this enzyme might play a role in colorectal cancer progression.

"Since studies here and elsewhere have shown the importance of COX-2 and colonic carcinogenesis, we postulated that maybe one of the mechanisms by which the normal colon might prevent excessive expression of COX-2 is by 11βHSD2," said Harris, the Ann and Roscoe R. Robinson Professor of Nephrology and director of the division. 


The researchers examined expression of 11βHSD2 in human colon polyps and in the colons of mice predisposed to colon cancer. They found that 11βHSD2 was increased in polyps found in both mice and humans and correlated with COX-2 expression and activity.

They then inhibited 11βHSD2 with glycyrrhizic acid, the main sweet-tasting component of licorice, and by silencing the gene for 11βHSD2.

Both treatments inhibited the production of prostaglandin E2 (an inflammatory molecule produced by the COX-2 enzyme) and prevented the development of polyps (adenomas) and tumor growth and metastasis.

Because 11βHSD2 is highly expressed only in kidney and colon, blocking the enzyme produces effects specific to those tissues unlike NSAIDs, selective COX-2 inhibitors, and steroid treatments that can prevent cancer progression but also cause serious side effects like gastrointestinal irritation, cardiovascular events, and immunosuppression, respectively.

Licorice, Harris noted, has been used as a nutraceutical for thousands of years for ailments ranging from coughs to constipation. But even licorice is not without side effects; long-term consumption can lead to low blood potassium and increases in blood pressure side effects linked to the inhibition of 11βHSD2.

"These are relatively minor compared to the cardiovascular side effects of COX-2 inhibitors," Harris said. "We didn't see (these side effects) in the mice we treatedbut it would be something to be aware of, and something that could easily be treated with a diuretic."

Harris and colleagues are continuing to investigate the mechanism of 11βHSD2 inhibition. Zhang, an assistant professor of Medicine and of Cancer Biology, also plans to look at the enzyme's role in lung cancer and other tumors.

And although this natural chemical is an appealing drug lead in itself, the researchers are also working with the Vanderbilt Institute for Chemical Biology to develop more specific and potent inhibitors of 11βHSD2.

"We think we can make (an inhibitor) that is more specific and has better delivery to the target tissues," Zhang said.


'/>"/>

Contact: Melissa Marino
melissa.marino@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
Source:Eurekalert

Related medicine news :

1. Licorice extract provides new treatment option for canker sores
2. TV crime drama compound highlights immune cells misdeeds
3. The Texas Institute of Dermatology Team Finds Easy-to-Apply, Topical Drug Just as Good as Injectable Compound for a Disfigurating Skin Infection
4. Chili Pepper Compound Can Bring Pain Relief
5. Compounds Found to Protect Rabbits From Cerebral Palsy
6. Compounds that trigger beta cell replication identified by JDRF funded researchers
7. Stunning finding: Compounds protect against cerebral palsy
8. Blood pressure compound may benefit brain tumor patients
9. Australias Leading Oncology Drug Compounder Chooses RIVA System
10. AstraZeneca Licenses Novel Antidepressant Compounds Discovered by Mayo Clinic and Virginia Tech Collaboration
11. HPS Establishes Independent Website for its Patent-Pending Mood-Enhancing Compound Naturally Found in Sea Coral
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2017)... ... 29, 2017 , ... Saturday, April 29, marks World Veterinary ... have on animal health and welfare as well as on public health. The ... a theme each year and this year have selected “Antimicrobial Resistance—From Awareness to ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... It's not ... are a number of illnesses that are unclear as to whether or not they ... heads. Bronchitis is one of these illnesses. So, FindaTopDoc took a look into the ...
(Date:4/28/2017)... ... ... much more than energy – it also has mental and physical benefits. According to the ... which can increase the risk of having a car accident. , This week is ... help you sleep better and feel better:, , Turn off all ...
(Date:4/28/2017)... VA (PRWEB) , ... April 28, 2017 , ... The ... volunteer board members and officers for 2017-2018. The annual board election process has been ... on a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, ...
(Date:4/28/2017)... Md. (PRWEB) , ... April 28, 2017 , ... ... Association of America (UCAOA) and College of Urgent Care Medicine will host industry ... workshops, sessions and speakers will help those in the industry adapt to the ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017 ... an immune response in pets such as canine, ... are of various types such as Attenuated Live ... Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated live ... virus or bacteria, which have been weakend under ...
(Date:4/18/2017)... , April 18, 2017  Cardinal Health (NYSE: ... 1 fiscal 2017 earnings per share (EPS) guidance ... 2019.  This is in conjunction with this morning,s announcement ... Vein Thrombosis and Nutritional Insufficiency businesses. Cardinal ... continuing operations will be at the bottom of its ...
(Date:4/18/2017)... -- Astute Medical, Inc., developer of biomarkers for better healthcare, ... the 2017 National Kidney Foundation (NKF) Spring Clinical ... 22. Physicians will present data on two biomarkers, ... acute kidney injury (AKI) during the management of patients ... Elevated levels of TIMP-2 and IGFBP-7 have been shown ...
Breaking Medicine Technology: